The HIV/HBV co-infected patient : time for proactive management

Simple item page
dc.contributor.authorAndersson, Monique I.en_ZA
dc.contributor.authorPreiser, Wolfgangen_ZA
dc.contributor.authorVan Rensburg, Christoen_ZA
dc.contributor.authorTaljaard, Jantjieen_ZA
dc.contributor.authorHoffmann, Christopher J.en_ZA
dc.contributor.otherPathology: Medical Virologyen_ZA
dc.date.accessioned2016-07-11T13:42:59Z
dc.date.available2016-07-11T13:42:59Z
dc.date.issued2015-02
dc.descriptionCITATION: Andersson, M.I. et al. 2015. The HIV/HBV co-infected patient: Time for proactive management. South African Medical Journal, 105(4):281-282, doi:10.7196/SAMJ.8907.en_ZA
dc.descriptionThe original publication is available at http://www.samj.org.zaen_ZA
dc.description.abstractHepatitis B virus (HBV) infection affects around 240 million people worldwide, with the highest prevalence of disease in Africa and Asia. Hepatocellular carcinoma (HCC) is the second most common cancer in men in Africa, and in around 75% of cases is associated with chronic HBV infection. HIV disproportionately affects sub-Saharan Africa. HIV/HBV co-infection is associated with worse outcomes than HBV monoinfection. Identifying patients who are co-infected enables assessment of liver health and the institution of HCC surveillance. HBV rapid tests are available and could be performed alongside HIV screening. Suppression of HBV viral load reduces complications and improves outcomes. Tenofovir has potent activity against HBV and is becoming increasingly available across sub-Saharan Africa as first-line therapy for HIV. HIV/HBV co-infected patients should be started on HBV active therapy, irrespective of CD4 count. Lifestyle modification, including weight management, avoidance of traditional herbal medication and alcohol restriction, improves liver health and should be encouraged. Confirmation of hepatitis A immunity is prudent. While access to more sensitive tests is limited in sub-Saharan Africa, alpha-fetoprotein and ultrasound scanning is advised for HCC surveillance. Screening and if necessary HBV vaccination of susceptible household and sexual contacts is indicated.en_ZA
dc.description.urihttp://www.samj.org.za/index.php/samj/article/view/8907en_ZA
dc.description.versionPublisher's versionen_ZA
dc.format.extent2 pages
dc.identifier.citationAndersson, M. I. et al. 2015. The HIV/HBV co-infected patient: Time for proactive management. South African Medical Journal, 105(4):281-282, doi:10.7196/SAMJ.8907en_ZA
dc.identifier.issn2078-5135 (online)
dc.identifier.issn0256-9574 (print)
dc.identifier.otherdoi:10.7196/SAMJ.8907.
dc.identifier.urihttp://hdl.handle.net/10019.1/99131
dc.language.isoen_ZA
dc.publisherHealth and Medical Publishing Groupen_ZA
dc.rights.holderThe South African Medical Journalen_ZA
dc.subjectHIV infectionsen_ZA
dc.subjectHepatitis Ben_ZA
dc.titleThe HIV/HBV co-infected patient : time for proactive managementen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
preiser_hiv_2015.pdf
Size:
71.27 KB
Format:
Adobe Portable Document Format
Description:
Download PDF
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Medical Virology)